MX360498B - Compuesto novedoso de pirimidina fusionada o sal del mismo. - Google Patents

Compuesto novedoso de pirimidina fusionada o sal del mismo.

Info

Publication number
MX360498B
MX360498B MX2016001845A MX2016001845A MX360498B MX 360498 B MX360498 B MX 360498B MX 2016001845 A MX2016001845 A MX 2016001845A MX 2016001845 A MX2016001845 A MX 2016001845A MX 360498 B MX360498 B MX 360498B
Authority
MX
Mexico
Prior art keywords
salt
pyrimidine compound
fused pyrimidine
present
novel fused
Prior art date
Application number
MX2016001845A
Other languages
English (en)
Other versions
MX2016001845A (es
Inventor
Satoru Iguchi
Takeshi Sagara
Hosoi Fumihito
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of MX2016001845A publication Critical patent/MX2016001845A/es
Publication of MX360498B publication Critical patent/MX360498B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Se proporciona un compuesto novedoso que tiene acción inhibidora de BTK y un efecto de supresión de la proliferación celular; también se proporciona un medicamento útil para la prevención y/o tratamiento de una enfermedad relacionada con BTK, particularmente cáncer, con base en la acción inhibidora de BTK; se describe un compuesto representado por la fórmula (I) [en donde R1 a R3, W, A, Y y Z respectivamente tienen los significados como se definió en la especificación], o una sal del mismo. (ver Fórmula).
MX2016001845A 2013-08-12 2014-08-11 Compuesto novedoso de pirimidina fusionada o sal del mismo. MX360498B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2013167600 2013-08-12
PCT/JP2014/071158 WO2015022926A1 (ja) 2013-08-12 2014-08-11 新規な縮合ピリミジン化合物又はその塩

Publications (2)

Publication Number Publication Date
MX2016001845A MX2016001845A (es) 2016-05-16
MX360498B true MX360498B (es) 2018-11-05

Family

ID=52468312

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016001845A MX360498B (es) 2013-08-12 2014-08-11 Compuesto novedoso de pirimidina fusionada o sal del mismo.

Country Status (22)

Country Link
US (1) US9580432B2 (es)
EP (1) EP2947086B1 (es)
JP (1) JP6035423B2 (es)
KR (1) KR101828187B1 (es)
CN (1) CN105452257B (es)
AU (1) AU2014307437B2 (es)
BR (1) BR112016002069B1 (es)
CA (1) CA2921208C (es)
DK (1) DK2947086T3 (es)
ES (1) ES2661733T3 (es)
HU (1) HUE036834T2 (es)
MX (1) MX360498B (es)
MY (1) MY171831A (es)
NO (1) NO2947086T3 (es)
PH (1) PH12015502737B1 (es)
PL (1) PL2947086T3 (es)
PT (1) PT2947086T (es)
RU (1) RU2666349C2 (es)
SG (1) SG11201600048VA (es)
TR (1) TR201802875T4 (es)
TW (1) TWI585089B (es)
WO (1) WO2015022926A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3069593T3 (en) 2013-08-23 2026-06-09 Neupharma Inc Quinazolin-8-yl derivatives for use in methods of treating melanoma, non-small cell lung cancer, thyroid cancer, ovarian cancer, or colon cancer
TWI605049B (zh) * 2015-01-30 2017-11-11 Taiho Pharmaceutical Co Ltd Novel salts of condensed pyrimidine compounds and their crystallization
DK3120852T3 (da) * 2015-01-30 2019-07-29 Taiho Pharmaceutical Co Ltd Præventivt og/eller terapeutisk middel til immunsygdomme
KR102075886B1 (ko) * 2015-09-01 2020-02-11 다이호야쿠힌고교 가부시키가이샤 신규한 피라졸로[3,4-d]피리미딘 화합물 또는 그 염
MA41559A (fr) 2015-09-08 2017-12-26 Taiho Pharmaceutical Co Ltd Composé de pyrimidine condensé ou un sel de celui-ci
US9834561B2 (en) * 2015-10-28 2017-12-05 Scinopharm Taiwan, Ltd. Process for preparing ibrutinib and its intermediates
DK3269370T3 (da) 2016-02-23 2020-04-06 Taiho Pharmaceutical Co Ltd Hidtil ukendt kondenseret pyrimidinforbindelse eller salt deraf
CN109843858B (zh) * 2016-08-15 2023-05-05 润新生物公司 某些化学实体、组合物及方法
JP7223684B2 (ja) * 2017-02-28 2023-02-16 大鵬薬品工業株式会社 ピラゾロ［３，４－ｄ］ピリミジン化合物を用いた抗腫瘍効果増強剤
EP3674325A4 (en) 2017-08-21 2021-11-03 Taiho Pharmaceutical Co., Ltd. FUSION PROTEIN OF DCTN1 PROTEIN WITH RET PROTEIN
PL3909584T3 (pl) * 2019-01-11 2024-03-25 Taiho Pharmaceutical Co., Ltd. Związek pirymidynowy lub jego sól
CA3129665A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
TWI895316B (zh) * 2019-12-19 2025-09-01 日商大鵬藥品工業股份有限公司 以縮合嘧啶化合物作為有效成分之治療劑
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
TW202216151A (zh) * 2020-07-15 2022-05-01 日商大鵬藥品工業股份有限公司 含有使用於腫瘤之治療之嘧啶化合物之組合
US20240100172A1 (en) 2020-12-21 2024-03-28 Hangzhou Jijing Pharmaceutical Technology Limited Methods and compounds for targeted autophagy
CN114736207B (zh) * 2022-04-28 2023-03-31 武汉九州钰民医药科技有限公司 一种小分子her2抑制剂的制备工艺

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007509939A (ja) 2003-10-27 2007-04-19 ジェネラブズ テクノロジーズ インコーポレーティッド ウイルス感染を治療するためのヌクレオシド化合物
WO2007067781A2 (en) 2005-12-08 2007-06-14 Abbott Laboratories 9-membered heterobicyclic compounds as inhibitors of protein kinases
US20100273776A1 (en) 2006-03-29 2010-10-28 FOLDRx PHARMACEUTICALS, INC Inhibition of alpha-synuclein toxicity
WO2008054827A2 (en) * 2006-11-03 2008-05-08 Pharmacyclics, Inc. Bruton's tyrosine kinase activity probe and method of using
EP2139487B1 (en) * 2007-03-28 2015-11-11 Pharmacyclics LLC Inhibitors of bruton's tyrosine kinase
WO2009057733A1 (ja) * 2007-10-31 2009-05-07 Santen Pharmaceutical Co., Ltd. 血管新生阻害活性を有する新規インドール誘導体
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
AU2009262068C1 (en) 2008-06-27 2015-07-02 Celgene Car Llc Heteroaryl compounds and uses thereof
KR20140048968A (ko) 2011-07-13 2014-04-24 파마시클릭스, 인코포레이티드 브루톤형 티로신 키나제의 억제제
WO2013010889A1 (en) * 2011-07-15 2013-01-24 Sanofi-Aventis Deutschland Gmbh A drug delivery device
AU2013210403B2 (en) 2012-01-19 2016-01-14 Taiho Pharmaceutical Co., Ltd. 3,5-disubstituted alkynylbenzene compound and salt thereof
CN104250250A (zh) * 2013-06-25 2014-12-31 苏州科捷生物医药有限公司 4-芳香胺基嘧啶类化合物及其抗肿瘤用途

Also Published As

Publication number Publication date
EP2947086B1 (en) 2018-01-03
EP2947086A1 (en) 2015-11-25
SG11201600048VA (en) 2016-03-30
WO2015022926A1 (ja) 2015-02-19
CN105452257B (zh) 2017-09-05
DK2947086T3 (en) 2018-03-19
CA2921208A1 (en) 2015-02-19
RU2015156524A (ru) 2017-09-14
PL2947086T3 (pl) 2018-06-29
TR201802875T4 (tr) 2018-03-21
CN105452257A (zh) 2016-03-30
JP6035423B2 (ja) 2016-11-30
PH12015502737A1 (en) 2016-03-07
HUE036834T2 (hu) 2018-08-28
BR112016002069B1 (pt) 2020-08-18
TW201536786A (zh) 2015-10-01
CA2921208C (en) 2018-02-20
PH12015502737B1 (en) 2018-08-31
US9580432B2 (en) 2017-02-28
US20160115168A1 (en) 2016-04-28
TWI585089B (zh) 2017-06-01
AU2014307437B2 (en) 2016-12-15
PT2947086T (pt) 2018-03-09
JPWO2015022926A1 (ja) 2017-03-02
KR20160038891A (ko) 2016-04-07
AU2014307437A1 (en) 2016-01-21
NO2947086T3 (es) 2018-06-02
ES2661733T3 (es) 2018-04-03
BR112016002069A2 (pt) 2017-08-01
RU2666349C2 (ru) 2018-09-07
KR101828187B1 (ko) 2018-02-09
EP2947086A4 (en) 2016-06-22
MY171831A (en) 2019-11-01
HK1217703A1 (zh) 2017-01-20
MX2016001845A (es) 2016-05-16

Similar Documents

Publication Publication Date Title
PH12015502737A1 (en) Novel fused pyrimidine compound or salt thereof
MX2022002579A (es) Compuestos de aminotiazol como inhibidores de c- kit.
PH12017502363A1 (en) Brk inhibitory compound
SG11201806930PA (en) Novel condensed pyrimidine compound or salt thereof
MX2015010125A (es) Derivados de piridazinona-amidas.
MX373865B (es) Compuesto novedoso de pirazolo[3,4-d] pirimidina o sal del mismo
MD20160106A2 (ro) Compuşi aril sau heteroaril biciclici condensaţi şi utilizarea acestora ca inhibitori IRAK4
PH12016500225B1 (en) Novel quinoline-substituted compound
PH12016501977A1 (en) 2-AMINO-6-METHYL-4,4a,5,6-TETRAHYDROPYRANO[3,4-d][1,3]THIAZIN-8a(8H)-YL-1,3-THIAZOL-4-YL AMIDES
MD4666B1 (ro) Inhibitori ai Syk
MX352928B (es) Compuestos de piridazina-amida.
MX367897B (es) Derivados de piridazinona macrociclicos.
BR112015000399A2 (pt) derivados de pirazolil pirimidina
PH12014502396B1 (en) Nitrogenated heterocyclic compound
MX362550B (es) Inhibidores ciclicos de glutaminasa.
UA113470C2 (xx) Піримідинові та піридинові сполуки та їх застосування
EP3587400A3 (en) Process for the preparation of a pde4 inhibitor
MX349548B (es) Compuestos de tienopirimidina.
EA201790207A8 (ru) Новые замещенные пиримидиновые соединения
MX366839B (es) Pirimidinas novedosas 2,5-sustituidas como inhibidores de pde4.
PH12016502130B1 (en) Novel pyrrolopyrimidine compound or salt thereof, pharmaceutical composition containing same, especially agent for prevention and/or treatment of tumors etc based on nae inhibitory effect
MX2015013936A (es) Compuestos de pirimidina condensada sustituida.
MX2017000522A (es) Pirimidinas novedosas 2,5-sustituidas como inhibidores de pde.
MX394038B (es) Derivados de pirrolotriazina como inhibidores de cinasas.
PH12017500492A1 (en) Crystalline bace inhibitors

Legal Events

Date Code Title Description
FG Grant or registration